CD44 and breast carcinoma: Consequently, breast cancer stem cells were evaluated using flow cytometry, revealing that the proportion of CD24-/CD44+ cells was significantly higher in alpelisib-resistant cells compared to parental cells, as well as protein levels of CD44 and c-Myc (Figure 3D-E).